Neutra Life Sciences Expands Clinical Research Capabilities Through New Joint Ventures

Neutra Corp's subsidiary, Neutra Life Sciences, has announced a significant expansion of its clinical research services through new joint venture partnerships. This strategic move includes collaborations with Epic Foot & Ankle Centers (http://www.epicfootandankle.com), Aspire Hospital Cancer Centers (http://www.aspirehealthcorp.com), and Radiant Dermatology & Aesthetics Clinic (http://www.radiantdermtx.com), covering podiatry, radiation oncology, and dermatology respectively. These partnerships are set to diversify Neutra Life Sciences' research capabilities, enabling it to address a wider range of clinical indications and meet the growing demand for specialized clinical research services.

The expansion into these medical specialties positions Neutra Life Sciences as a versatile player in the clinical research industry, capable of supporting Contract Research Organizations (CROs) and Sponsors across various therapeutic areas. Sydney Jim, President and CEO of Neutra Corp, emphasized the importance of these partnerships in fostering innovation in patient care and research, highlighting the company's commitment to delivering high-quality, integrated clinical research solutions.

Furthermore, Neutra Corp has decided to divest its hemp-based cannabis subsidiary, VIVIS Corporation, to concentrate its resources and leadership on the burgeoning life sciences sector. This decision underscores the company's strategic pivot towards areas with greater regulatory stability and long-term growth potential, particularly in clinical research and life sciences technology.

Neutra Life Sciences' expansion and the strategic divestiture of VIVIS Corporation reflect Neutra Corp's dedication to advancing healthcare innovation and improving health outcomes through cutting-edge research and collaboration. The company's focus on building a robust network of clinical research sites and enhancing its service offerings demonstrates its commitment to playing a pivotal role in the development of innovative treatments across a broad spectrum of therapeutic areas.